Goldman Sachs Group Inc Coherus Bio Sciences, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 331,117 shares of CHRS stock, worth $566,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

331,117

Previous 547,707 39.54%

Holding current value

$566,210

Previous $443,000 45.6%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.72 - $1.12 $155,944 - $242,580	-216,590 Reduced 39.54%	331,117 $241,000
Q1 2025 May 09, 2025	BUY	$0.81 - $1.66 $10,527 - $21,575	12,997 Added 2.43%	547,707 $443,000
Q4 2024 Feb 11, 2025	SELL	$0.67 - $1.71 $1.03 Million - $2.64 Million	-1,542,933 Reduced 74.26%	534,710 $737,000
Q3 2024 Nov 14, 2024	SELL	$0.99 - $1.8 $81,564 - $148,298	-82,388 Reduced 3.81%	2,077,643 $2.16 Million
Q2 2024 Aug 13, 2024	BUY	$1.58 - $2.51 $703,822 - $1.12 Million	445,457 Added 25.98%	2,160,031 $3.74 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.14 $1.77 Million - $2.75 Million	876,999 Added 104.71%	1,714,574 $4.1 Million
Q4 2023 Feb 13, 2024	SELL	$1.59 - $3.85 $769,855 - $1.86 Million	-484,186 Reduced 36.63%	837,575 $2.79 Million
Q3 2023 May 14, 2024	BUY	$3.74 - $5.45 $1.81 Million - $2.64 Million	484,186 Added 57.81%	1,321,761 $4.94 Million
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $2.98 Million - $4.34 Million	797,200 Added 151.97%	1,321,761 $4.94 Million
Q2 2023 May 14, 2024	SELL	$3.79 - $8.3 $577,857 - $1.27 Million	-152,469 Reduced 22.52%	524,561 $2.24 Million
Q2 2023 Aug 14, 2023	SELL	$3.79 - $8.3 $577,857 - $1.27 Million	-152,469 Reduced 22.52%	524,561 $2.24 Million
Q1 2023 May 14, 2024	SELL	$5.89 - $10.52 $144,670 - $258,392	-24,562 Reduced 3.5%	677,030 $4.63 Million
Q1 2023 May 11, 2023	SELL	$5.89 - $10.52 $144,670 - $258,392	-24,562 Reduced 3.5%	677,030 $4.63 Million
Q4 2022 May 14, 2024	SELL	$5.69 - $10.07 $401,884 - $711,244	-70,630 Reduced 9.15%	701,592 $5.56 Million
Q4 2022 Feb 13, 2023	SELL	$5.69 - $10.07 $401,884 - $711,244	-70,630 Reduced 9.15%	701,592 $5.56 Million
Q3 2022 May 14, 2024	BUY	$7.17 - $13.87 $1.23 Million - $2.38 Million	171,247 Added 28.49%	772,222 $7.42 Million
Q3 2022 Nov 10, 2022	BUY	$7.17 - $13.87 $1.23 Million - $2.38 Million	171,247 Added 28.49%	772,222 $7.42 Million
Q2 2022 May 14, 2024	SELL	$5.86 - $13.23 $1.39 Million - $3.13 Million	-236,600 Reduced 28.25%	600,975 $4.35 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $740,211 - $1.67 Million	126,316 Added 26.61%	600,975 $4.35 Million
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $967,260 - $1.45 Million	-88,577 Reduced 15.73%	474,659 $6.13 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $1.41 Million - $1.69 Million	-89,250 Reduced 13.68%	563,236 $8.99 Million
Q3 2021 Nov 10, 2021	BUY	$12.68 - $17.79 $8.27 Million - $11.6 Million	652,486 New	652,486 $10.5 Million

Others Institutions Holding CHRS

# of Institutions

120

Shares Held

58.2M

Call Options Held

89.3K

Put Options Held

31K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $133M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Coherus Bio Sciences, Inc. Transaction History